| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc79128866a504732fc0b460f497e104
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d59d1b6df6a274aff96193d289f8464
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c80e9ee7abb697626114befd8ee546b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_791d2f5ee16b7c895ea510949051b9fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b4a36c764cdd580a57c85108f1baaed5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-44 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2007-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9beae8a014ba4b6ea7d786ea0b740433
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94525fef9c16da86e2fbdcad9edf8c95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9ffce791381647b0ed9e5df536f614d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6baefa81deb6ab589476d8cd471822be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4acea774712c06b3db46898afcff193b |
| publicationDate |
2010-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010143380-A1 |
| titleOfInvention |
Compositions and methods for macular degeneration |
| abstract |
The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the. agent inhibits ocular angiogenesis in the individual. In another embodiment, the invention is directed to methods of inhibiting choroidal neovascularization in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the agent inhibits choroidal neovascularization in the individual. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018093797-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11739326-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11229662-B2 |
| priorityDate |
2006-07-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |